<?xml version="1.0" encoding="UTF-8"?>
<p>The Good Participatory Practice Guidelines for Emerging Pathogens (GPP‐EP) provides guidance for developing systems that can guide stakeholder engagement in the design, financing, and implementation of prevention and treatment trials during health emergencies. The guidelines recognize that stakeholder engagement in the clinical trials could strengthen the epidemic response, and
 <fn id="dewb12283-note-1012">
  <label>12</label>
  <p>World Health Organization, op. cit. note 7.</p>
 </fn> stakeholder engagement in research conducted during epidemics is an ethical imperative. A collaborative approach to research blends the lived experiences and expertise of interested laypersons with the expertise of the research enterprise, the power of policymakers, and rigorous science. As we have argued elsewhere,
 <fn id="dewb12283-note-1013">
  <label>13</label>
  <p>Folayan, M.O., Allman, D., Haire, B., et al. (2018). Considerations for community engagement when conducting clinical trials during infectious disease emergencies in West Africa. Dev World Bioeth. 1–10.</p>
 </fn> stakeholder engagement in the design and implementation of trials during epidemics is an ethical imperative; the urgency to respond to emergencies and the nature of these emergencies should not preclude engaging stakeholders in the design, implementation, and monitoring of clinical trials.
</p>
